Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*

被引:14
|
作者
Brivio, Erica [1 ,2 ]
Chantrain, Christophe F. [3 ]
Gruber, Tanja A. [4 ,5 ]
Thano, Adriana [1 ]
Rialland, Fanny [6 ]
Contet, Audrey [7 ]
Elitzur, Sarah [8 ]
Dalla-Pozza, Luciano [9 ]
Kallay, Krisztian Miklos [10 ]
Li, Chi-kong [11 ]
Kato, Motohiro [12 ]
Markova, Inna [13 ]
Schmiegelow, Kjeld [14 ,15 ]
Bodmer, Nicole [16 ]
Breese, Erin H. [17 ,18 ]
Hoogendijk, Raoull [1 ]
Pieters, Rob [1 ]
Zwaan, Christian Michel [1 ,2 ]
机构
[1] Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands
[3] CHC Clin Mt Legia Liege, Div Pediat Hematol Oncol, Liege, Belgium
[4] Stanford Sch Med, Dept Pediat, Stanford, CA 94305 USA
[5] Stanford Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA
[6] CHU Nantes, Dept Oncol & Hematol, Nantes, France
[7] CHRU Nancy, Dept Oncol & Hematol, Childrens Hosp, Vandoeuvre Les Nancy, France
[8] Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Tel Aviv, Israel
[9] Childrens Hosp Westmead, Canc Ctr Children, Westmead, NSW, Australia
[10] Cent Hosp Southern Pest, Pediat Hematol & Stem Cell Transplantat Dept, Natl Inst Hematol & Infect Dis, Budapest, Hungary
[11] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China
[12] Natl Res Inst Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan
[13] Pavlov Univ, RM Gorbacheva Mem Inst Children Oncol Hematol & T, St Petersburg, Russia
[14] Copenhagen Univ Hosp, Dept Pediat & Adolescent Med, Rigshosp, Copenhagen, Denmark
[15] Univ Copenhagen, Fac Hlth, Inst Clin Med, Copenhagen, Denmark
[16] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland
[17] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[18] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
关键词
infants; ALL; inotuzumab ozogamicin;
D O I
10.1111/bjh.17333
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22(+) blasts was 72% (range 40-100%, n = 9). The median dose in the first course was 1.74 mg/m(2) (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27-80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.
引用
收藏
页码:1172 / 1177
页数:6
相关论文
共 50 条
  • [1] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Brivio, Erica
    Hoogendijk, Raoull
    Chantrain, Christophe
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian
    Li, Chi Kong
    Kato, Motohiro
    Markova, Inna V.
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Pieters, Rob
    Zwaan, Christian Michel
    [J]. BLOOD, 2019, 134
  • [2] Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
    Zaina T. Al-Salama
    [J]. Targeted Oncology, 2018, 13 : 525 - 532
  • [3] Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
    Al-Salama, Zaina T.
    [J]. TARGETED ONCOLOGY, 2018, 13 (04) : 525 - 532
  • [4] Inotuzumab ozogamicin in acute lymphoblastic leukaemia
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2019, 20 (05): : E248 - E248
  • [5] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    [J]. LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [6] Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin
    Cassaday, Ryan D.
    Marks, David I.
    DeAngelo, Daniel J.
    Jabbour, Elias J.
    Advani, Anjali S.
    O'Brien, Susan
    Wang, Tao
    Neuhof, Alexander
    Vandendries, Erik
    Kantarjian, Hagop M.
    Stock, Wendy
    Stelljes, Matthias
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (03) : E77 - E81
  • [7] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    [J]. IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [8] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    [J]. Leukemia, 2019, 33 : 884 - 892
  • [9] Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia
    Morley, N. J.
    Marks, D. I.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 159 - 164
  • [10] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Marks, David, I
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    Jabbour, Elias
    Merchant, Akil
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop
    O'Brien, Susan
    [J]. BLOOD CANCER JOURNAL, 2020, 10 (08)